These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26527820)

  • 61. Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: Approaches based on its medicinal chemistry.
    Bastos MM; Costa CCP; Bezerra TC; da Silva FC; Boechat N
    Eur J Med Chem; 2016 Jan; 108():455-465. PubMed ID: 26708112
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Anti-HIV-1 activity determined by β-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method.
    Miyamoto F; Kawaji K; Oishi S; Fujii N; Kaku M; Kodama EN
    Antivir Chem Chemother; 2015 Apr; 24(2):77-82. PubMed ID: 26527820
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of three quantification methods for the TZM-bl pseudovirus assay for screening of anti-HIV-1 agents.
    Xing L; Wang S; Hu Q; Li J; Zeng Y
    J Virol Methods; 2016 Jul; 233():56-61. PubMed ID: 27016178
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.
    Pirounaki M; Heyden NA; Arens M; Ratner L
    J Virol Methods; 2000 Mar; 85(1-2):151-61. PubMed ID: 10716348
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synthesis and evaluation of 3-hydroxy-3-phenylpropanoate ester–AZT conjugates as potential dual-action HIV-1 Integrase and Reverse Transcriptase inhibitors.
    Manyeruke MH; Olomola TO; Majumder S; Abrahams S; Isaacs M; Mautsa N; Mosebi S; Mnkandhla D; Hewer R; Hoppe HC; Klein R; Kaye PT
    Bioorg Med Chem; 2015 Dec; 23(24):7521-8. PubMed ID: 26775541
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.
    Shimane K; Kawaji K; Miyamoto F; Oishi S; Watanabe K; Sakagami Y; Fujii N; Shimura K; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
    Antimicrob Agents Chemother; 2013 Aug; 57(8):4035-8. PubMed ID: 23689710
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
    Izumi K; Kawaji K; Miyamoto F; Shimane K; Shimura K; Sakagami Y; Hattori T; Watanabe K; Oishi S; Fujii N; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
    Int J Biochem Cell Biol; 2013 Apr; 45(4):908-15. PubMed ID: 23357451
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
    Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.
    Kawamoto A; Kodama E; Sarafianos SG; Sakagami Y; Kohgo S; Kitano K; Ashida N; Iwai Y; Hayakawa H; Nakata H; Mitsuya H; Arnold E; Matsuoka M
    Int J Biochem Cell Biol; 2008; 40(11):2410-20. PubMed ID: 18487070
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
    Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
    J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
    Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
    Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
    [No Abstract]   [Full Text] [Related]  

  • 74. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
    Wei X; Decker JM; Liu H; Zhang Z; Arani RB; Kilby JM; Saag MS; Wu X; Shaw GM; Kappes JC
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1896-905. PubMed ID: 12019106
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
    Maeda K; Yoshimura K; Shibayama S; Habashita H; Tada H; Sagawa K; Miyakawa T; Aoki M; Fukushima D; Mitsuya H
    J Biol Chem; 2001 Sep; 276(37):35194-200. PubMed ID: 11454872
    [TBL] [Abstract][Full Text] [Related]  

  • 76. 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
    Kodama EI; Kohgo S; Kitano K; Machida H; Gatanaga H; Shigeta S; Matsuoka M; Ohrui H; Mitsuya H
    Antimicrob Agents Chemother; 2001 May; 45(5):1539-46. PubMed ID: 11302824
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
    Maeda Y; Venzon DJ; Mitsuya H
    J Infect Dis; 1998 May; 177(5):1207-13. PubMed ID: 9593005
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.
    Platt EJ; Wehrly K; Kuhmann SE; Chesebro B; Kabat D
    J Virol; 1998 Apr; 72(4):2855-64. PubMed ID: 9525605
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.